share_log

Jupiter Neurosciences Announces Strategic Focus On NLRP3 Inflammasome Targeting In Clinical Trials For Neurodegenerative Diseases With JOTROL Platform

Jupiter Neurosciences Announces Strategic Focus On NLRP3 Inflammasome Targeting In Clinical Trials For Neurodegenerative Diseases With JOTROL Platform

木星神經科學宣佈在針對神經退行性疾病的臨牀試驗中,戰略性專注於NLRP3炎性小體靶向治療,使用JOTROL平台。
Benzinga ·  01/13 13:31

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, today announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims to unlock new therapeutic potential for neurodegenerative diseases, longevity, and aging, positioning the Company at the forefront of innovation in neuroinflammation treatments.

木星神經科學公司(納斯達克:JUNS)("木星"或"公司")是一家臨牀階段的藥品公司,正在開發JOTROL,這是一種專利的基於白藜蘆醇的平台,今天宣佈將戰略重點放在針對NLRP3炎症小體的所有即將進行的臨牀試驗上。這一轉變旨在爲神經退行性疾病、長壽和衰老Unlock新的治療潛力,使公司處於神經炎症治療創新的前沿。

The NLRP3 inflammasome is a key inflammation driver linked to central nervous system (CNS) disorders, metabolic diseases, and aging-related conditions. JOTROL, Jupiter's flagship product, overcomes resveratrol's historical challenges of poor bioavailability and gastrointestinal side effects. With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3.

NLRP3炎症小體是一個與中樞神經系統(CNS)疾病、新陳代謝疾病和衰老相關病症相關的重要炎症驅動因素。JOTROL,木星的旗艦產品,克服了白藜蘆醇歷史上生物利用度差和胃腸道副作用的挑戰。憑藉其安全達到血漿治療水平並突破血腦屏障的能力,JOTROL代表了針對如NLRP3這樣的神經炎症通路的突破性進展。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 330

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。